David King Stephens, MD
Epilepsy · Orange, CANPI 1700973633
Payments from drug & device makers
Across 878 payments — averaging $751.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$210K
- SK Life Science, Inc.$87K
- UCB SA$85K
- Neurelis, Inc.$80K
- Catalyst Pharmaceuticals, Inc.$49K
- Eisai Inc.$44K
- plus $105K from 22 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 334 | $210,092 |
| SK Life Science, Inc. | 143 | $87,431 |
| UCB SA | 11 | $85,479 |
| Neurelis, Inc. | 125 | $80,383 |
| Catalyst Pharmaceuticals, Inc. | 42 | $48,520 |
| Eisai Inc. | 66 | $43,587 |
| Ceribell, Inc. | 4 | $30,750 |
| Medtronic(2 entities) | 15 | $22,513 |
| Neuropace, Inc. | 38 | $18,455 |
| Greenwich Biosciences, Inc. | 23 | $8,891 |
| Livanova USA, Inc. | 18 | $7,341 |
| Aquestive Therapeutics, Inc. | 8 | $5,824 |
| Biogen | 2 | $3,950 |
| Shire North American Group Inc | 3 | $3,230 |
| Zimmer Biomet | 8 | $1,089 |
| UCB Biosciences Inc. | 2 | $1,050 |
| Jazz Pharmaceuticals Inc. | 7 | $807 |
| ZOLL Medical Corporation | 1 | $233 |
| Sunovion Pharmaceuticals Inc. | 15 | $138 |
| Neurocrine Biosciences, Inc. | 2 | $55 |
| Teva Pharmaceuticals USA, Inc. | 2 | $49 |
| Lilly USA, LLC | 2 | $45 |
| Bausch Health US, LLC | 2 | $28 |
| Adamas Pharmaceuticals, Inc. | 1 | $27 |
| Avanir Pharmaceuticals, Inc. | 1 | $24 |
| Amgen | 1 | $22 |
| Upsher-smith Laboratories LLC | 1 | $19 |
| Supernus Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$660,044 in reported general payments places this provider in the 95th percentile of 46 epilepsy providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other epilepsy in Orange
- Mona SazgarOrange$343K
- Lilit MnatsakanyanOrange$125K
- Kurt QingOrange$7K
- Brian JungOrange$3K
- Doris DengOrange$3K
- Robert FisherStanford$463K
- Josef ParviziStanford$438K
- Kimford MeadorStanford$432K
- David Leela Jolla$64K
- William GallentinePalo Alto$60K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.